12:00 AM
 | 
Jan 03, 2011
 |  BC Week In Review  |  Company News  |  Deals

Arrowhead, M.D. Anderson Cancer Center deal

The center granted Arrowhead an exclusive, worldwide license to technology related targeting the prohibitin 1 (PHB1) to treat weight-loss and obesity-related metabolic conditions. Arrowhead...

Read the full 107 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >